Pfizer Ltd.'s net profit fell by 2% in the third quarter of the current fiscal. The pharmaceutical company posted a bottom line of Rs 127.6 crore, as compared to Rs 130 crore for the same period last year, according to an exchange filing on Friday.
The company recorded a revenue of Rs 538 crore for the October-December period, down marginally by 0.4% from Rs 540 crore in the third quarter of the previous fiscal.
Pfizer posted earnings before interest, taxes, depreciation and amortisation of Rs 146 crore, down 4% from Rs 152.6 crore in the year-ago period. The margins contracted to 27.1% from 28.3%.
Pfizer Q3 FY25 Earnings Highlights (YoY)
Revenue slips 0.4% to Rs 538 crore versus Rs 540 crore.
Ebitda down 4% at Rs 146 crore versus Rs 152.6 crore.
Margin at 27.1% versus 28.3%.
Net profit falls 2% to Rs 127.6 crore versus Rs 130 crore.
The quarterly results were declared after the market hours. Shares of Pfizer closed 0.17% higher at Rs 4,526.7 apiece on the National Stock Exchange, compared to a 1.11% advance in the benchmark Nifty 50. The stock has risen by 4.98% in the last 12 months.
Out of the three analysts tracking the company, two have a 'buy' rating on the stock and one recommends 'hold', according to Bloomberg data. The average of 12-month analysts' consensus price target implies a potential upside of 38.5%.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
